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26 This investigation presents the characterization and evaluation of the physicochemical and 
27 microbiological properties of a new multicomponent complex of ketoconazole. Complex 
28 formation of the drug, with proline and β-cyclodextrin, was evaluated using nuclear magnetic 
29 resonance and phase solubility studies. The complex, in solid state, was prepared through 
30 kneading and physical mixture and then characterized by Fourier transform infrared 
31 spectroscopy, differential scanning calorimetry and scanning electron microscopy. By means 
32 of confocal laser scanning microscopy, the effect of proline on the morphology of Candida 
33 albicans was evaluated. Microbiological assays were performed to evaluate the antifungal 
34 activity of the complex against C. albicans. The results obtained from phase solubility assays 
35 showed that the complexation of ketoconazole is an effective strategy to enhance its 
36 solubility. Confocal laser scanning microscopy demonstrated that proline severely affected 
37 Candida morphology, and microbiological studies established high antifungal activity for the 
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50 1. INTRODUCTION
51 Recently, an increase in the prevalence and incidence of invasive fungal infections has been 
52 reported, with Candida as one of the most common genera causing infections [1]. Candida is 
53 an opportunistic type of yeast that causes severe disease in immunocompromised individuals. 
54 For example, oropharyngeal candidiasis is a frequent infection of individuals undergoing 
55 immunosuppressive therapy for cancer, organ transplantation and in AIDS patients [2,3]. The 
56 common treatment of candidiasis is associated with several side effects that limit the dose and 
57 dosing frequency. Therefore, new drugs and drug formulations that permit the reduction in 
58 dose and mitigation of side effects are urgently required for the efficient management of 
59 Candida infections [4].
60 Ketoconazole (KET, Fig. 1A), a dibasic imidazole synthetic agent with a broad spectrum of 
61 antifungal activity, is used to treat mycotic infections, including candidiasis [5]. KET is 
62 classified as a class II drug in the Biopharmaceutics Classification System, because of its low 
63 solubility and high permeability. Its’ limited water solubility generates problems in the 
64 preparation of pharmaceutical formulations and limits its bioavailability and therapeutic 
65 applications. 
66 Many technologies that improve the solubility of drugs that are poorly water-soluble have 
67 been developed, such as the incorporation of cyclodextrins (CDs) [6]. CDs are, in fact, water 
68 soluble cyclic oligosaccharides composed of 6 (α-CD), 7 (β-CD, Figure 1B) or 8 (γ-CD) D-
69 (+)-glucopyranose units, arranged in a truncated cone shaped structure. Different molecules 
70 can penetrate into the relatively hydrophobic cavity and form non covalent inclusion 
71 complexes, thus modifying their physical, chemical and biological properties [7-11]. In 
72 previous work, the preparation and characterization of KET complexes with CDs were 
73 reported. The researchers demonstrated that these inclusion complexes were an effective way 
74 to increase the solubility of KET [12-15]. In addition, in recent years the use of 
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75 multicomponent complexes with CDs and a third auxiliary substance has become more 
76 popular, in order to facilitate the therapeutic application of different drugs [6, 16-20]. With 
77 regard to KET, multicomponent complexes were prepared with acids compounds as the third 
78 compound and compared to a binary system demonstrating the multicomponent systems a 
79 better pharmaceutical performance [13, 21, 22]. Amino acids are widely used in chemical, 
80 microbiological and pharmaceutical fields, and their incorporation into CD complexes has 
81 been reported to be an effective technology for enhancing the solubility and bioavailability of 
82 compounds with poor water solubility [23]. We have previously reported that glycine and 
83 cysteine increase chloramphenicol solubility by formation of a multicomponent complex with 
84 β-CD that modulates reactive oxygen species production induced by this drug in leukocytes 
85 [24].
86 The aim of this study was to investigate the influence of the complexation of KET with β-CD 
87 and L-Proline (PRO) (Fig. 1C) on its solubility in aqueous solutions and antifungal activity. 
88 PRO was selected because it induces germ tube-forming cells in C. albicans cultures, which 
89 are more sensitive to azole-induced killing than the yeast cell itself, whereby a synergistic 
90 effect between KET and PRO could be observed [25]. Phase solubility analyses and nuclear 
91 magnetic resonance spectroscopy were used to determine the effects of complexation on drug 
92 solubility and affinity constant. The complexes, in solid state, were prepared by the kneading 
93 and physical mixture methods and then characterized by Fourier transform infrared 
94 spectroscopy, scanning electron microscopy and thermal analysis. A microbiological in vitro 
95 assay of KET and the KET:β-CD:PRO multicomponent complex was performed using C. 
96 albicans, an important clinical pathogen. The inhibition zone diameter, in each case, was 
97 measured, and the obtained value served as a measure of the antifungal activity of KET. In 
98 addition, confocal laser scanning microscopy (CLSM) was used to evaluate the effect of PRO 
99 on C. albicans morphology.
ACCEPTED MANUSCRIPT
100 2. MATERIALS AND METHODS
101 2.1. Chemicals and reagents
102 KET and PRO were obtained from Todo Droga (Argentina). β-CD (MW = 1135) was kindly 
103 supplied by Roquette (France). Dimethyl sulfoxide-D6 (99.8 %) MagniSolv™ deuterated 
104 solvent was obtained from Merck (Switzerland). All other materials and solvents were of 
105 analytical reagent grade. A Milli-Q Water Purification System (Millipore, USA) generated the 
106 water used in these studies.
107
108 2.2. Phase solubility analysis
109 Experiments were carried out in stoppered glass tubes containing an excess amount of KET 
110 (15 mg) and 5 ml of increasing concentrations of β-CD (0–13.2 mM) in the presence of PRO 
111 (10 mM), according to the method reported by Higuchi and Connors [26]. The tubes were 
112 placed in a 37.0 (±0.1) ºC thermostatized shaker (Ferca) for 72 h at 130 rpm, until 
113 complexation equilibrium was reached. Each sample suspension was filtered through a 0.45 
114 µm membrane (Millipore), and the concentration of KET in the filtered solutions was 
115 measured by UV spectrophotometry at 225 nm (Agilent Cary 50 spectrophotometer). Each 
116 experiment was repeated at least three times, and the results reported were the mean values. 
117 The Kc value for the corresponding KET complex was calculated from the slope of the phase-
118 solubility diagrams and intrinsic solubility (S0) according to Eq. (1):
119 Kc= slope / S0 (1- slope)                Eq. (1)
120
121 2.3. NMR studies
122 The NMR spectra of pure compounds and the multicomponent system were recorded on a 
123 Bruker Avance II high resolution spectrometer equipped with a broad band inverse probe 
124 (BBI) and a variable temperature unit (VTU). The spectra were measured at 298 K. DMSO 
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125 deuteration degree min 99.8% was used as solvent. Induced changes in the 1H chemical shifts 
126 for KET, β-CD and PRO, which originated due to their complexation, were calculated using 
127 the following equation Eq. (2):
128 ∆δ = δcomplex - δfree Eq. (2)
129
130 2.4. Preparation of complexes in solid state
131 The solid complexes of KET with β-CD and PRO, in a 1:1:1 molar ratio, were prepared using 
132 the kneading (K) and physical mixture (PM) methods:
133 a) Kneading: KET, β-CD, and PRO powders, in a 1:1:1 molar ratio, were mixed and then 
134 crushed with a mortar and pestle, adding a water:ethanol solution (1:1 v/v). The mix was 
135 kneaded for 30 min and then dried at 45 °C for 24 h.
136 b) Physical mixture: was prepared by uniformly mixing KET with β-CD and PRO powders in 
137 a mortar in a 1:1:1 molar ratio.
138
139 2.5. Fourier transform infrared spectroscopy (FTIR)
140 FTIR spectra of KET, β-CD, PRO and the complex (KBr disks) were recorded on a Nicolet 
141 Avatar 360 FTIR spectrometer. The spectrum of the complex was compared with those of 
142 pure KET, β-CD, PRO and the corresponding physical mixture. All spectra were obtained and 
143 processed using EZ OMNIC E.S.P v.5.1 software.
144
145 2.6. Differential Scanning Calorimetry (DSC) and Thermogravimetry (TG)
146 The thermogravimetry (TG) test of sample was recorded on a TG Discovery series instrument 
147 (TA, USA), and the differential scanning calorimeter (DSC) test was recorded on a DSC 
148 Discovery series instrument (TA, USA). The thermal behaviour was studied by heating 1-2 
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149 mg of the samples in perforated aluminium capsules in a nitrogen atmosphere, in the 
150 temperature range of 25-200°C (DSC) and 25-350°C (TG) at a heating rate of 10°C min-1.
151
152 2.7. Scanning electron microscopy studies (SEM)
153 Microscopic morphological structures of the solid samples were investigated and 
154 photographed using a Carl Zeiss Σigma scanning electron microscope, at the Laboratorio de 
155 Microscopía y Análisis por Rayos X (LAMARX) of the National University of Córdoba. The 
156 samples were fixed on a brass stub using double-sided aluminium tape, and to improve the 
157 conductivity, they were gold/palladium-coated under vacuum, employing a sputter coater 
158 Quorum 150. The magnification selected was sufficient to appreciate, in detail, the general 
159 morphology of the samples under study.
160
161 2.8. Analysis of cell morphology of Candida albicans using confocal laser scanning 
162 microscopy (CLSM)
163 To evaluate the effect of PRO on cell morphology, two clinical isolates of C. albicans (strains 
164 216 and 256, identified by a battery of biochemical tests) were grown on 2% Sabouraud agar 
165 (24 h at 37 °C), with and without PRO (at two concentrations 10 or 100 mM). A drop of the 
166 suspended culture was transferred on a slide, fixed and stained with safranin. The samples 
167 were examined by confocal laser scanning microscopy (Olympus OLS4100) with a sufficient 
168 magnification to appreciate, in detail, the morphology of the C. albicans cells.
169
170 2.9. Microbiological assay 
171 Antimicrobial susceptibility tests were performed by the agar diffusion method according to 
172 Marzouk et al., [15] with some modifications. Microorganisms and inoculum cultures of C. 
173 albicans were cultivated on 2% Sabouraud agar and maintained in test tubes in a refrigerator 
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174 at 4 ± 2 °C until use. The microorganisms were suspended in 0.9 % NaCl; the concentration 
175 of the obtained suspension was adjusted to 0.08-0.1 of absorbance at 600 nm, using a 
176 spectrophotometer analyser (~107 colony forming units per millilitres, Shimadzu UV-Mini 
177 1240 spectrophotometer). The surface of the agar plates was spread using a sterile swab 
178 soaked in the bacterial suspension. A 6-mm disk of sterile Whatman N°1 membrane filter 
179 resting on an agar culture medium was inoculated with 5 μl of solution containing free or 
180 complexed KET (7 µg) and KET:PRO. Aqueous solutions of pure β-CD and PRO were used 
181 as controls. The plates were incubated at 37 °C for 24 h. The resulting zone diameters of 
182 growth inhibition were then measured in mm. Each determination was performed in triplicate, 
183 statistics values were expressed as the mean ± the standard deviation of each group. The 
184 difference between three means was compared by a two-tailed unpaired Student's t test. P 
185 values of < 0.05 were considered significant.
186
187 3. RESULTS AND DISCUSSION
188 3.1. Behaviour of the multicomponent complex in aqueous solution
189 3.1.1. Phase solubility analysis (PSA)
190 In order to determine the influence of β-CD and PRO on KET solubility, the phase-solubility 
191 diagram was determined. The phase solubility profile of KET with β-CD and PRO can be 
192 classified as AL type, according to Higuchi and Connors. [26] These profiles showed a linear 
193 increase of drug solubility (data not shown), when the concentration of β-CD increased, 
194 which is indicative of the formation of soluble complexes. The corresponding stability 
195 constant value, calculated from phase-solubility diagram, was 4966 ± 93 M-1, and the 
196 increases in drug solubility were of 65-fold (S0 0.0094 mg/ml and Smax 0.609 mg/ml).
197
198 3.1.2. NMR studies
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199 NMR studies were performed to confirm the inclusion complex formation and to gain insight 
200 into the structure of the multicomponent complex. In Table 1, the assignments of the KET, β-
201 CD and PRO peaks and the chemical shift displacement (Δδ) due to complexation (for NMR 
202 signal notation see Fig. 1) are shown. The changes observed in NMR signals clearly indicated 
203 the compound interactions (Fig. 2). In the case of β-CD, the inner protons (H3 and H5) 
204 undergo an upfield shift that can be attributed to magnetic anisotropy effects caused by the 
205 KET inclusion. Furthermore, OH2 and OH3 protons of β-CD showed a marked shielding 
206 effect that suggested that some moiety of KET and/or PRO molecules can interact with the 
207 macromolecule’s wide rim, possibly establishing hydrogen bond interactions. In addition, the 
208 protons of the dichlorophenyl (H24 and H26) and phenolic (H10-14 and H11-13) rings of KER 
209 exhibited significant upfield shifts, indicating its penetration inside the β-CD cavity. These 
210 observations are consistent with the existence of two different inclusion modes for the 
211 complex. The downfield observed for the KET imidazole ring (H30, H31 and H33) and PRO 
212 (H, H and H) protons, may be due to conformational changes produced by the interaction 
213 between compounds.
214
215 3.2. Behaviour of the multicomponent complex in solid state
216 3.2.1. Fourier transform infrared spectroscopy (FTIR)
217 In order to confirm whether KET could interact with PRO and β-CD, IR spectrum analysis of 
218 pure compounds, and systems prepared by kneading and physical mixture, were developed. 
219 As shown in Fig. 3A, the IR spectrum of pure KET was characterized by absorption peaks at 
220 1645 cm-1 (C˭O stretching vibration), 1583 cm-1 (aromatic C˭C stretching vibration) and 1512 
221 and 1457 cm-1 (benzene cycle vibration). The IR spectrum of β-CD (Fig. 3B) showed 
222 prominent absorption bands at 3365 cm–1, (O-H stretching vibration) while strong bands of 
223 pure PRO (Fig. 2C) appeared at 1619 cm−1 (asymmetric COO− stretching vibration) and 1401 
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224 cm−1 (symmetric COO− stretching vibration). The spectra of multicomponent systems 
225 prepared by PM (Fig. 3D) or K (Fig. 3E) did not show any new peaks, indicating no chemical 
226 bond formation in these systems. The IR spectrum of the PM system did not significantly 
227 differ from those of the single components, indicating that there is almost no interaction 
228 between these compounds when physically mixed. On the other hand, in the IR spectrum of 
229 the system prepared by K, a widening and a marked shift of the characteristic absorption 
230 bands of KET was observed, compared with the pure drug. It was possible to observe that the 
231 bands of PRO are almost masked by the very intense and broad β-CD and KET bands 
232 although can be observed the modification that appear at 1619 cm−1 in pure PRO. These 
233 findings indicated the presence of interactions between the KET, β-CD and PRO in this 
234 system.
235 3.2.2. Differential Scanning Calorimetry (DSC) and Thermogravimetry (TG) 
236 The DSC and TG curves of pure components and multicomponent systems are shown in Fig. 
237 4. It can be observed that KET presents a sharp endothermic peak at 149.8 °C, attributable to 
238 the melting process of the crystalline form of the drug, which begins to decompose at about 
239 320 °C. PRO and βCD lost water at temperatures between 25–100 °C (Δm= 5% and 7.5%, 
240 respectively), with decomposition taking place above 200 °C (PRO) and 300 °C (β-CD), as 
241 evidenced by the mass loss observed in the TG curve. TG curves of KET:β-CD:PRO PM and 
242 K systems show a similar behaviour with three steps of weight loss, one due to dehydration 
243 (Δm= 7.1% PM and 4.6 % K), a second event related to PRO decomposition (Δm= 7% PM 
244 and  K) and the third corresponding to the drug and β-CD decomposition taking place above 
245 300°C. In the DSC curve KET:β-CD:PRO PM, it is possible to observe the endothermic event 
246 corresponding to the melting point of the drug at 148.2 °C. On the other hand, the thermal 
247 peak of the drug in the KET:β-CD:PRO K curve, appeared at a lower temperature (142.2 °C), 
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248 accompanied by a reduction in its fusion enthalpy, suggesting that a partial drug 
249 amorphization occurred in this system that can be related to the complexation.
250
251 3.2.3. Scanning electron microscopy (SEM)
252 The shape and structure of KET complexes prepared by the K method were assessed by SEM 
253 (Fig. 5), and were compared with the pure materials and KET systems prepared by PM. In 
254 SEM images of KET:β-CD:PRO K, it was observed that these products had a significantly 
255 different morphology, with respect to the pure materials and the PM, and it was not possible 
256 to differentiate the single components. These solids showed small size particles, compared 
257 with the pure compounds. On the other hand, the characteristic KET crystals, which were 
258 mixed with β-CD particles and PRO, were clearly detectable in the SEM images of the PM, 
259 thus confirming the presence of the crystalline drug and the absence of interactions.
260
261 3.3. Confocal laser scanning microscopy (CLSM) observation 
262 The effect of PRO on C. albicans morphology was evaluated by CLSM after the incubation of 
263 the yeast strains with PRO at two concentrations (10 and 100 mM). The alteration on cellular 
264 morphology was visually confirmed by CLSM, which showed a unicellular, oval-shaped 
265 diploid fungus in both strains when not treated with PRO (control, Fig. 6. a and d). The dose-
266 dependent interference of PRO with the morphology of C. albicans could be clearly seen in 
267 strain 216. In the case of treatment with PRO 10 mM (Fig. 6 b), it was possible to observe 
268 some cells with altered morphology, while for the treatment with PRO 100 mM (Fig. 6 c), a 
269 cell pattern with totally altered morphology was evident. In strain 256, only 100 mM of PRO 
270 altered its morphology (Fig. 6 f). This microscopic observation confirms the ability of PRO to 
271 induce germ tube formation and morphological changes in C. albicans. [25]
272
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273 3.4. Microbiological assay 
274 The antifungal activity of KET, β-CD, PRO, PRO:β-CD, KET:PRO, KET:β-CD and KET:β-
275 CD:PRO was studied in C. albicans 216 and 256 clinical pathogen isolates. The diffusion 
276 agar method was used for this study. β-CD and PRO used as negative control did not show 
277 inhibition halos (data not shown). In Fig. 7, we can observe the microbiological data from 
278 KET, KET:PRO, KET:β-CD and the KET:β-CD:PRO complex. β-CD, PRO, PRO:β-CD. 
279 β-CD, PRO and PRO: β-CD were used as control and did not present inhibition halo.
280 The antifungal activity of the KET:β-CD:PRO multicomponent complex was significantly 
281 higher than KET and that of KET:β-CD and KET:PRO, suggesting a synergistic effect 
282 between PRO and KET, solubilized by the presence of β-CD. It is known that the formation 
283 of inclusion complexes is able to increase, decrease or maintain the biological activity, 
284 depending on the balance between microscopic or macroscopic effects. Indeed, on the 
285 microscopic scale, inclusion leads to the reduction of free drug, whereas on the macroscopic 
286 scale, complexation of slightly soluble drug considerably improves its water solubility, which 
287 can increase the available drug concentration. In this work despite the high Kc value obtain 
288 for the complex (4966 ± 93 M-1), the microbiological activity was increased assessing the 
289 ability of β-CD to release the drug. Moreover, it was suggested that CD molecules might 
290 destabilize the outer membrane of the microorganisms, which eventually leads to an increase 
291 of the diffusion rate of antimicrobials [27]. Furthermore, this synergy may be attributable to 
292 the presence of PRO that altered the C. albicans morphology, as could be observed by CLSM. 
293 This increase in the antifungal activity of the KET:β-CD:PRO multicomponent complex is the 




297 In this work, the KET:β-CD:PRO  multicomponent complexes were prepared in solution and 
298 solid state and characterized by PSA, NMR, FTIR, SEM and DSC studies. The results 
299 obtained showed that the formation of a multicomponent complex of KET with β-CD and 
300 PRO produces an important increase in the aqueous solubility of this antifungal drug. 
301 Moreover, PRO induces alterations in the cellular morphology of C. albicans. It can be 
302 suggesting that the synergy of both effects results in the highest antifungal activity observed 
303 for the KET:β-CD:PRO complex. Thus, this multicomponent complex is an interesting 
304 candidate for the preparation of KET dosage forms, with improved antifungal activity.
305
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Figure legends
Figure 1: Chemical structure and proton atom assignment scheme of: (A) KET, (B) β-
CD, (C) PRO.
Figure 2. 1H NMR Spectra of (A) KET, (B) βCD, (C) PRO and (D) KET:βCD:PRO 
system. 
Figure 3. IR spectra of: a) KET, b) β-CD, c) PRO, d) KET:β-CD:PRO K, e) KET:β-
CD:PRO PM.
Figure 4. DSC and TG curves of KET (fuchsia), β-CD (green), PRO (black), 
KET:βCD:PRO K system (blue) and KET:βCD:PRO PM system (turquoise).
Figure 5. Scanning electron microphotographs of: (a) KET, (b) β-CD, (c) PRO, (d) 
KET:βCD:PRO K (e) KET:βCD:PRO PM.
Figure 5. Confocal laser scanning microscopy of: (a) strain 216 control, (b) strain 216 
with PRO 10 mM, (c) strain 216 with PRO 100 mM, (d) strain 256 control (e) strain 256 
with PRO 10 mM and f) strain 256 with PRO 100 mM.
Figure 7: Histogram of the mean values of the inhibition zones diameters of KET, 
KET:PRO, KET:β-CD and KET:β-CD:PRO. White column, Candida albicans 256; black 
column, C. albicans 216. *p < 0.05 with respect to KET, # p < 0.05 compared to 
KET:PRO, ~ p < 0.05 compared to KET:β-CD
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Highlights
• KET complex with β-cyclodextrin and Proline was prepared and characterized
• The water solubility of KET was improved
•The antifungal activity was increase by multicomponent complex formation










Table 1: Chemical shifts for the protons of KET, β-CD and PRO in the free and complex 
form.
KET protons δ (ppm) δ (ppm) KET:-CD:PRO Δδ (ppm)
H1 2.0312       2.0298 -0.0014
H4-8     - overlapped      -
H5-7     - overlapped      -
H16     - overlapped      -
H21     - overlapped      -
H17 4.3359 4.3359      0
H28 4.5262 4.5253 -0.0009
H11-13 6.7956 6.7926 -0.0003
H31 6.8136 6.8140 0.0004
H10-14 6.9113 6.9086 -0.0027
H30 7.0083 7.0093 0.0010
H26 7.4523 7.4509 -0.0014
H33 7.4728 7.4779 0.0051
H27 7.5657 7.5657     0
H24 7.6837 7.6811 -0.0026
-CD protons
H1 4.8241 4.8276 0.0035
H2     - overlapped      -
OH2 5.7216 5.7943 0.0727
H3 3.6284 3.6347 -0.0063
OH3 5.6699 5.7437 0.0738
H4     - overlapped      -
H5 3.5576 3.5569 -0.0007
H6 3.6284 3.6347 -0.0063
OH6     - overlapped      -
PRO protons
H     - overlapped      -
H 1.9691 1.9834 0.0143
H 1.7205 1.7427 0.0222
H     - overlapped     -
3.2057 3.2078 0.0021
